Chronic Conditions

Drugs & Pharmaceuticals

Effects of the SGLT2 Inhibitor Dapagliflozin on Proteinuria in Non-Diabetic Patients With Chronic Kidney Disease (DIAMOND): A Randomised, Double-Blind, Crossover Trial.

July 1, 2020

By Hannah Branch

Homepage
>
Publications
>
Effects of the SGLT2 Inhibitor Dapagliflozin on Proteinuria in Non-Diabetic Patients With Chronic Kidney Disease (DIAMOND): A Randomised, Double-Blind, Crossover Trial.

Cherney DZI, Dekkers CCJ, Barbour SJ, Cattran D, Gafor AHA, et al., for the DIAMOND investigators

Tell us what you think Cancel reply